Insmed Incorporated (NASDAQ:INSM) Insider Martina M.D. Flammer Sells 3,344 Shares

Insmed Incorporated (NASDAQ:INSM) insider Martina M.D. Flammer sold 3,344 shares of the company’s stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $65.91, for a total value of $220,403.04. Following the sale, the insider now owns 102,766 shares of the company’s stock, valued at approximately $6,773,307.06. This trade represents a 3.15 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Martina M.D. Flammer also recently made the following trade(s):

• On Friday, January 10th, Martina M.D. Flammer sold 6,172 shares of Insmed stock. The stock was sold at an average price of $63.64, for a total value of $392,786.08.

Insmed Price Performance

NASDAQ INSM traded down $0.47 during trading on Friday, reaching $65.25. 3,087,759 shares of the company traded hands, compared to its average volume of 1,881,810. Insmed Incorporated has a 1-year low of $21.92 and a 1-year high of $80.53. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37. The stock’s 50 day moving average price is $71.29 and its two-hundred day moving average price is $72.44. The company has a market cap of $11.67 billion, a price-to-earnings ratio of -11.76 and a beta of 1.12.

Insmed (NASDAQ:INSM) last announced its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($1.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.19) by ($0.08). The business had revenue of $93.40 million during the quarter, compared to analysts’ expectations of $93.36 million. Insmed’s revenue for the quarter was up 18.1% on a year-over-year basis. During the same quarter last year, the business earned ($1.10) EPS. As a group, analysts anticipate that Insmed Incorporated will post -5.44 EPS for the current year.

Analyst Upgrades and Downgrades

INSM has been the subject of a number of analyst reports. Bank of America boosted their price objective on shares of Insmed from $84.00 to $86.00 and gave the stock a “buy” rating in a research note on Wednesday, October 9th. JPMorgan Chase & Co. upped their price target on shares of Insmed from $74.00 to $83.00 and gave the company an “overweight” rating in a report on Friday, November 22nd. Truist Financial reiterated a “buy” rating and issued a $105.00 price objective (up from $100.00) on shares of Insmed in a research note on Friday, November 1st. Finally, HC Wainwright restated a “buy” rating and set a $90.00 target price on shares of Insmed in a research note on Friday, November 1st. One investment analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Insmed presently has an average rating of “Moderate Buy” and an average target price of $83.67.

Institutional Investors Weigh In On Insmed

A number of hedge funds have recently made changes to their positions in INSM. Harbor Capital Advisors Inc. grew its stake in Insmed by 237.1% during the fourth quarter. Harbor Capital Advisors Inc. now owns 59,600 shares of the biopharmaceutical company’s stock worth $4,115,000 after buying an additional 41,918 shares during the last quarter. Everence Capital Management Inc. acquired a new position in shares of Insmed in the 4th quarter worth approximately $352,000. Principal Financial Group Inc. grew its position in Insmed by 12.9% during the 3rd quarter. Principal Financial Group Inc. now owns 1,871,890 shares of the biopharmaceutical company’s stock worth $136,648,000 after acquiring an additional 214,130 shares during the last quarter. Tidal Investments LLC increased its holdings in Insmed by 447.0% during the 3rd quarter. Tidal Investments LLC now owns 24,102 shares of the biopharmaceutical company’s stock valued at $1,759,000 after purchasing an additional 19,696 shares in the last quarter. Finally, Sanctuary Advisors LLC bought a new position in Insmed in the 3rd quarter valued at $248,000.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.